Results
Title

Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.

Authors

Singh-Kandah, Shahnaz; Kaiwen Wang; Xia, Karen; Johnson, Andy Lain; D'Andrea, Denise M.; Shu, Catherine A.; Dougherty, Lindsay Bray; Gallitano, Stephanie M.

Abstract

BACKGROUND: Amivantamab is an epidermal growth factor receptor (EGFR) and MET bispecific antibody approved for certain patients with advanced non-small cell lung cancer with EGFR variant. Cutaneous toxicities are known on-target effects of EGFR inhibition. OBJECTIVES: This article describes the occurrence and management of cutaneous toxicities in patients whose disease progressed on platinum chemotherapy treated with amivantamab. METHODS: Post hoc analysis evaluated incidence, severity, and time to first onset of rash and paronychia. Five nurses and advanced practice providers were interviewed. FINDINGS: Of 380 patients, 296 (78%) experienced treatment-related rash and/or paronychia. Paronychia (43%), rash (36%), and dermatitis acneiform (35%) were most frequent, with scalp rash reported by 17%. Treatment modifications because of rash and paronychia were infrequent.

Subjects

THERAPEUTIC use of antineoplastic agents; DRUG toxicity; MEDICAL protocols; RISK assessment; DATA analysis; SKIN diseases; ANTINEOPLASTIC agents; EXANTHEMA; DESCRIPTIVE statistics; SEVERITY of illness index; CANCER chemotherapy; STATISTICS; QUALITY of life; LUNG cancer; PARONYCHIA; EPIDERMAL growth factor receptors; DISEASE risk factors

Publication

Clinical Journal of Oncology Nursing, 2024, Vol 28, Issue 6, p559

ISSN

1092-1095

Publication type

Academic Journal

DOI

10.1188/24.CJON.559-566